Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance on Ocrezlizumab for treating relapsing-remitting multiple sclerosis informed by SHTAC report

Published: 25 July 2018
Wheelchair user
People in their 40s - 50s are the most likely to be diagnosed with MS

The National Institute for Health and Care Excellence (NICE) has issued guidance to the national health service (NHS) on the use of the drug Ocrelizumab for treating relapsing–remitting multiple sclerosis in adults.

The guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

NICE's guidance recommends Ocrelizumab as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if:

  • alemtuzumab is contraindicated or otherwise unsuitable and
  • the company provides ocrelizumab according to the commercial arrangement.

This recommendation is not intended to affect treatment with ocrelizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

For more information about SHTAC’s previous research into multiple sclerosis please visit our Research page.

Privacy Settings